Industry

Industry — The Sterile Injectables CDMO Playing Field

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, multiples, and percentages are unitless and unchanged.

Onyx Biotec operates in B2B sterile pharmaceutical contract manufacturing: it fills injectable medicines and sterile water into vials, ampoules, and dry-powder packs for other pharma companies who put their own brand on the carton. Globally, sterile-injectables contract manufacturing is a $15-17 billion market growing at high single digits, driven by branded pharma's reluctance to build $300 million aseptic suites for assets with 10% clinical success rates (Mordor Intelligence, 2026). In India, the same logic plays out at a different altitude: a fragmented field of 100+ regional sterile CDMOs supplies India's branded generics giants — Sun Pharma, Mankind, Cipla, Macleods — who rent sterile capacity rather than lock crore-scale capex behind a single product line. The newcomer's misread is to call this "pharma": it is specialist industrial manufacturing for pharma, with cement-plant unit economics dressed up in clean rooms.

1. Industry in One Page

The industry's job is to take chemistry someone else invented and reproduce it, in glass, with zero microbial contamination, at scale. The brand owner keeps the patient, the prescriber, and most of the dollar. The contract manufacturer keeps the line throughput and the audit risk.

2. How This Industry Makes Money

The revenue model is per-unit conversion: the CDMO is paid a price per vial or per ampoule that covers raw materials, sterile labour, depreciation on the clean room, and a conversion margin. The brand owner sells the same vial downstream at 5-15x what the CDMO billed — that gap is the prescription brand's economics, not the manufacturer's.

Inside the CDMO slot, the cost stack is fixed-heavy: HVAC for the cleanroom runs whether one batch a week or ten; depreciation runs from day one; skilled QA/QC labour cannot be flexed without losing WHO-GMP discipline. Variable costs are mostly API and primary packaging. Profitability is therefore a utilisation game, not a price game — which explains why Caplin Point at 34-35% OPM and Onyx at 4-5% sit in the same industry but at opposite ends of the utilisation curve.

Key terms a beginner should hold in their head:

CDMO = Contract Development and Manufacturing Organisation; "loan licensing" is the local Indian version where the brand owner brings the dossier and the factory runs the line. Sterile = guaranteed bacteria-free, achieved either through Blow-Fill-Seal / Form-Fill-Seal (BFS / FFS) plastics, or aseptic fill of glass vials in Grade A cleanrooms. WHO-GMP = the minimum quality stamp for Indian export to most regulated and semi-regulated markets; the higher bar is US FDA, EU EMA, or UK MHRA — Onyx has WHO-GMP but not the higher Western approvals. SWFI = Sterile Water for Injection — a low-price commodity used to reconstitute powder drugs; the entry-level injectable product. Cephalosporins = a family of beta-lactam antibiotics (Ceftriaxone, Cefuroxime, Cefepime, etc.) that dominate Indian hospital antibiotic spend; Onyx's Unit II is dedicated to this chemistry.

3. Demand, Supply, and the Cycle

This is not a commodity cycle. It is end-market-cyclical with a long fixed-cost lag: demand is anchored to chronic-disease and hospital-antibiotic prescription volumes, which only fall in extreme stress (e.g. a Covid-style elective-surgery freeze). What does cycle, and hits earnings first, is the utilisation and pricing of capacity when several mid-sized CDMOs build similar lines simultaneously.

The cycle shows up first in utilisation, then debtor days, then operating margin. A CDMO with falling utilisation can hold revenue flat for a while (existing contracts continue) while operating profit collapses because the fixed-cost denominator does not shrink. Onyx's FY2026 is exactly this geometry: sales grew ~12% to $7.4M, but operating margin fell from 16.8% to 4.9% and the company swung to a small net loss as Unit II's ramp absorbed depreciation, interest, and audit costs faster than revenue arrived.

4. Competitive Structure

The Indian sterile-injectables CDMO field is highly fragmented at the bottom and consolidating at the top. A handful of large, exportable, US-FDA-compliant CDMOs (Gland Pharma, Akums, Caplin Point) sit above a long tail of regional WHO-GMP-only players selling domestically and into semi-regulated export markets. Onyx is in the long tail, with around $7M of revenue against listed peers' $233-686M.

The shape of the field: the top of the market earns 25-35% operating margins on scale, regulatory access (FDA/EMA), and a product mix tilted to complex injectables. The bottom — where Onyx sits — earns single-digit operating margins because fixed costs eat too much of a sub-$10M revenue line. The middle (Cohance, Akums) earns 12-19% by being big enough to spread overheads but lacking the export-grade premium that Caplin Point or Gland command. Crossing from the bottom into the middle is the entire investment question.

Tracxn ranks Onyx 387th out of 878 active competitors in its broader Indian pharma comp set, with Akums #1 — and notably, Akums is also one of Onyx's customers (it loan-licenses certain dosage forms to Onyx). Customer-and-competitor overlap is normal in CDMO; it tightens dependence but also signals trust.

5. Regulation, Technology, and Rules of the Game

Regulation is the moat and the cost of doing business. The same WHO-GMP audit that keeps small competitors out is the audit that can collapse a CDMO's revenue base on one bad inspection.

Two regulatory facts to anchor on: (1) Schedule M's 2024 revision is forcing the bottom of the Indian sterile manufacturing pyramid to either upgrade or exit, structurally bullish for surviving WHO-GMP holders like Onyx but only if they have the capital to keep up; and (2) the Indian PLI scheme is shifting incentives upstream toward KSM/API, not toward fill-finish, so the policy tailwind for pure sterile fillers is more about a cleaner supply chain than direct subsidy.

6. The Metrics Professionals Watch

Three of these — capacity utilisation, operating margin, and debtor days — carry the business almost entirely.

7. Where Onyx Biotec Limited Fits

Onyx is a sub-scale, regional, WHO-GMP-only sterile CDMO at the early-growth stage. It has the right product mix (SWFI as base load, cephalosporin DPI and syrups as the growth leg), the right customer roster on paper (Sun, Mankind, Hetero, Macleods, Akums itself), and a credible Solan / Himachal Pradesh manufacturing cluster around it. What it does not yet have is the scale to defend the fixed-cost stack of Unit II, the export footprint to escape Indian tender pricing, or the FDA-grade product mix that gives Gland and Caplin their 25-35% margins.

Whether Onyx is a stock idea is a question about utilisation at Unit II, not a question about whether sterile injectables CDMO is a good industry. The industry is structurally fine; the position inside it is fragile until proven.

8. What to Watch First

Five to seven observable signals will tell a reader, in roughly the order they show up, whether the industry backdrop is improving or deteriorating for Onyx specifically.